Oropharyngeal Cancer
Conditions
Brief summary
To determine the sensitivity of HPV OncotectTM to diagnose oropharyngeal cancers induced by oncogenic HPV
Interventions
DIAGNOSTIC_TESTHPV OncoTect™
Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test. Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results.
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Untreated oropharynx epidermoid carcinoma 2. Patient ≥ 18 years old 3. Patient affiliated to a social security scheme or beneficiary of such a scheme 4. Information to the patient or his legal representative and signature of informed consent
Exclusion criteria
1. Non-oropharyngeal epidermoid carcinoma 2. Oropharyngeal epidermoid carcinoma previously treated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity is defined as the probability that the oncotectTM HPV test is positive if the cancer is HPV-induced. | up to 12 months |
Countries
France
Contacts
Primary ContactHaitham MIRGHANI, MD
Outcome results
None listed